Chunhua Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chunhua Yang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Lijun Mao
Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China
5 shared publications Sai Ma
Xuzhou Med Univ, Dept Urinary Surg, Affiliated Hosp, Xuzhou 221000, Jiangsu, Peoples R China
3 shared publicationsYirui Liu
Xuzhou Med Univ, Dept Urinary Surg, Affiliated Hosp, Xuzhou 221000, Jiangsu, Peoples R China
3 shared publicationsDongliang Yang
Xuzhou Med Univ, Dept Urinary Surg, Affiliated Hosp, Xuzhou 221000, Jiangsu, Peoples R China
2 shared publicationsFukun Wei
Xuzhou Med Univ, Dept Urinary Surg, Affiliated Hosp, Xuzhou 221000, Jiangsu, Peoples R China
2 shared publicationsHaiyuan Yu
Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China
2 shared publications
Latest Publications
- Open Access
- 22 December 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 822
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
High expression of immune checkpoint molecule B7-H3 (CD276) in many cancer types makes it a promising immunotherapeutic target. Both coinhibitory and costimulatory effects of B7-H3 in tumors have been demonstrated, but the mechanism of B7-H3 immune response under dual effects is open to question. B7-H3 is crucially involved in the migration and invasion, angiogenesis, metabolism and chemotherapy resistance of prostate cancer. In addition to the potential immune effects on tumor environment, B7-H3 plays a non-immune-mediated role in tumor progression. In this review, we summarize current understanding of molecular mechanism of B7-H3 in prostate cancer and discuss the potential of B7-H3 as a novel therapeutic target for prostate cancer.
- 22 December 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 822
Open AccessImmune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
High expression of immune checkpoint molecule B7-H3 (CD276) in many cancer types makes it a promising immunotherapeutic target. Both coinhibitory and costimulatory effects of B7-H3 in tumors have been demonstrated, but the mechanism of B7-H3 immune response under dual effects is open to question. B7-H3 is crucially involved in the migration and invasion, angiogenesis, metabolism and chemotherapy resistance of prostate cancer. In addition to the potential immune effects on tumor environment, B7-H3 plays a non-immune-mediated role in tumor progression. In this review, we summarize current understanding of molecular mechanism of B7-H3 in prostate cancer and discuss the potential of B7-H3 as a novel therapeutic target for prostate cancer.
- Open Access
- 28 October 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (20) , 6570-6576
Prostate cancer stem cells: an updated mini-review
Prostate cancer is the most common malignant tumor in male genitourinary system. The incidence of prostate cancer ranks the first among all male malignant tumors worldwide, and the mortality rate ranks the second among all male malignant tumors. Prostate stem cells are heterogeneous subsets with the function of self-regeneration and proliferation in the prostate, which can produce all cell lineages that make up the prostate epithelium. At present, the pathogenesis of prostate cancer remains unclear. According to cancer stem cell hypothesis, prostate cancer may be a stem cell disease, which provides a new direction for revealing the pathogenesis of prostate cancer and developing treatment strategy for prostate cancer. In this mini-review, we highlight recent advances in our understanding of the origin, surface molecular markers, signaling pathway and the significance for clinical treatment of prostate cancer stem cells.
- 28 October 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (20) , 6570-6576
Open AccessProstate cancer stem cells: an updated mini-review
Prostate cancer is the most common malignant tumor in male genitourinary system. The incidence of prostate cancer ranks the first among all male malignant tumors worldwide, and the mortality rate ranks the second among all male malignant tumors. Prostate stem cells are heterogeneous subsets with the function of self-regeneration and proliferation in the prostate, which can produce all cell lineages that make up the prostate epithelium. At present, the pathogenesis of prostate cancer remains unclear. According to cancer stem cell hypothesis, prostate cancer may be a stem cell disease, which provides a new direction for revealing the pathogenesis of prostate cancer and developing treatment strategy for prostate cancer. In this mini-review, we highlight recent advances in our understanding of the origin, surface molecular markers, signaling pathway and the significance for clinical treatment of prostate cancer stem cells.
- 1 November 2021
- Vol. 32 (167) , 133-139
Oncolytic Virus as a Novel Modality for the Treatment of Prostate Cancer
Prostate cancer is the second most common malignant tumor in the world, with an incidence rate of 13.5% and a mortality rate of 6.7%. At present, treatment methods for prostate cancer include surgical treatment, endocrine therapy, chemotherapy, and radiotherapy. However, the efficacy of these treatments is not optimal, especially for advanced metastatic prostate cancer. Oncolytic virus has emerged as a novel therapeutic approach for cancer treatment due to its unique advantages such as high selectivity, high efficiency, and low toxicity. The replication ability of oncolytic virus in normal cells is low, while the virus can multiply specifically in tumor cells, which are lysed by the proliferation of the virus, and the induction of apoptosis. In addition, the released progeny virus can infect the surrounding tumor cells and eventually kill the tumor. In this review, we summarize the state-of-the-art progresses and propose new avenues in the development and application of oncolytic virus for the treatment of prostate cancer.
- 1 November 2021
- Vol. 32 (167) , 133-139
Oncolytic Virus as a Novel Modality for the Treatment of Prostate Cancer
Prostate cancer is the second most common malignant tumor in the world, with an incidence rate of 13.5% and a mortality rate of 6.7%. At present, treatment methods for prostate cancer include surgical treatment, endocrine therapy, chemotherapy, and radiotherapy. However, the efficacy of these treatments is not optimal, especially for advanced metastatic prostate cancer. Oncolytic virus has emerged as a novel therapeutic approach for cancer treatment due to its unique advantages such as high selectivity, high efficiency, and low toxicity. The replication ability of oncolytic virus in normal cells is low, while the virus can multiply specifically in tumor cells, which are lysed by the proliferation of the virus, and the induction of apoptosis. In addition, the released progeny virus can infect the surrounding tumor cells and eventually kill the tumor. In this review, we summarize the state-of-the-art progresses and propose new avenues in the development and application of oncolytic virus for the treatment of prostate cancer.
- 1 July 2021
- Vol. 32 (165) , 29-37
Emerging Roles of Long Non-coding RNAs as Novel Biomarkers in the Diagnosis and Prognosis of Prostate Cancer
New biomarkers for early diagnosis and prognosis are important in improving the diagnosis of metastatic or recurrent prostate cancer. Recent studies have shown important roles of long non-coding RNAs (lncRNAs) in tumorigenesis. Here we provide a comprehensive review of lncRNAs implicated in prostate cancer and discuss their potential as novel biomarkers and therapeutic targets for prostate cancer. In particular, we focus on lncRNAs associated with the androgen/androgen receptor pathway and the epithelial-to-mesenchymal transition. Notably, several lncRNAs such as PCA3, PCAT18, HOTAIR, and CCAT2 are prostate cancer-specific in that they are only upregulated in prostate cancer, and consequently they are promising biomarkers for use in clinical practice.
- 1 July 2021
- Vol. 32 (165) , 29-37
Emerging Roles of Long Non-coding RNAs as Novel Biomarkers in the Diagnosis and Prognosis of Prostate Cancer
New biomarkers for early diagnosis and prognosis are important in improving the diagnosis of metastatic or recurrent prostate cancer. Recent studies have shown important roles of long non-coding RNAs (lncRNAs) in tumorigenesis. Here we provide a comprehensive review of lncRNAs implicated in prostate cancer and discuss their potential as novel biomarkers and therapeutic targets for prostate cancer. In particular, we focus on lncRNAs associated with the androgen/androgen receptor pathway and the epithelial-to-mesenchymal transition. Notably, several lncRNAs such as PCA3, PCAT18, HOTAIR, and CCAT2 are prostate cancer-specific in that they are only upregulated in prostate cancer, and consequently they are promising biomarkers for use in clinical practice.
- Open Access
- 1 January 2021
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 12 (6) , 1846-1852
Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
Background: Oncolytic viral therapy is a new strategy for tumor eradication which combines the advantages of viral therapy and gene therapy. Silencing SATB1 exhibits strong inhibitory effect on the growth of prostate cancer. Docetaxel (DTX) is the gold standard for chemotherapy of prostate cancer, but its side effects decrease the life quality of patients. Therefore, it is urgent to develop combination therapy to increase its anti-tumor effect.
- 1 January 2021
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 12 (6) , 1846-1852
Open AccessCombination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
Background: Oncolytic viral therapy is a new strategy for tumor eradication which combines the advantages of viral therapy and gene therapy. Silencing SATB1 exhibits strong inhibitory effect on the growth of prostate cancer. Docetaxel (DTX) is the gold standard for chemotherapy of prostate cancer, but its side effects decrease the life quality of patients. Therefore, it is urgent to develop combination therapy to increase its anti-tumor effect.
- Open Access
- 3 April 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 421
Combination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation
Prostate cancer is a common malignant tumor and the second leading cause of cancer-related death in men. Radiation therapy is a curative treatment for localized prostate cancer and has a limited effect for castration-resistant prostate cancer (CRPC). Interleukin 24 (IL-24) has a radiosensitizing effect in cancer cells. Our previous studies showed that ZD55-IL-24, an oncolytic adenovirus harboring IL-24, had better anti-tumor effect with no toxicity to normal cells. In this study, we evaluated the synergistic anti-tumor effect of oncolytic adenovirus ZD55-IL-24 combined with radiotherapy in prostate cancer. In Vitro and In Vivo experiments showed that the combined therapy significantly inhibited the growth of prostate cancer and provoked apoptosis of prostate cancer cells. In conclusion, the combination of ionizing radiation and oncolytic adenovirus expressing IL24 could achieve synergistic anti-tumor effect on prostate cancer, and is a promising strategy for prostate cancer therapy.
- 3 April 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 421
Open AccessCombination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation
Prostate cancer is a common malignant tumor and the second leading cause of cancer-related death in men. Radiation therapy is a curative treatment for localized prostate cancer and has a limited effect for castration-resistant prostate cancer (CRPC). Interleukin 24 (IL-24) has a radiosensitizing effect in cancer cells. Our previous studies showed that ZD55-IL-24, an oncolytic adenovirus harboring IL-24, had better anti-tumor effect with no toxicity to normal cells. In this study, we evaluated the synergistic anti-tumor effect of oncolytic adenovirus ZD55-IL-24 combined with radiotherapy in prostate cancer. In Vitro and In Vivo experiments showed that the combined therapy significantly inhibited the growth of prostate cancer and provoked apoptosis of prostate cancer cells. In conclusion, the combination of ionizing radiation and oncolytic adenovirus expressing IL24 could achieve synergistic anti-tumor effect on prostate cancer, and is a promising strategy for prostate cancer therapy.
- 1 June 2019
- Vol. 27 (150) , 235-243
Current State of Biomarkers for the Diagnosis and Assessment of Treatment Efficacy of Prostate Cancer
In recent years, with the westernization of lifestyle, reduced physical activity and increased prostate-specific antigen (PSA) testing, the incidence of prostate cancer (PCa) has risen significantly in developing countries. Currently, PSA is the only PCa biomarker applied clinically, but it does not perform well in the early diagnosis and distinguishing between benign prostatic hyperplasia and prostate cancer. With the advances in deep sequencing technology, a series of new PCa biomarkers have been recently proposed to improve the diagnostic value of PSA, such as prostate cancer antigen 3 (PCA3), TMPRSS2-ETS fusion gene, microRNA, and other regulatory non-coding RNAs. In addition, the prostate health index (PHI) has been approved by the U.S. Food and Drug Administration (FDA) for clinical use in the detection of PCa. The prostate-specific membrane antigen (PSMA) has been confirmed to be specifically expressed on the surface of PCa cells. In this review, we provide an updated summary of the value and features of these novel biomarkers in the diagnosis and treatment of PCa.
- 1 June 2019
- Vol. 27 (150) , 235-243
Current State of Biomarkers for the Diagnosis and Assessment of Treatment Efficacy of Prostate Cancer
In recent years, with the westernization of lifestyle, reduced physical activity and increased prostate-specific antigen (PSA) testing, the incidence of prostate cancer (PCa) has risen significantly in developing countries. Currently, PSA is the only PCa biomarker applied clinically, but it does not perform well in the early diagnosis and distinguishing between benign prostatic hyperplasia and prostate cancer. With the advances in deep sequencing technology, a series of new PCa biomarkers have been recently proposed to improve the diagnostic value of PSA, such as prostate cancer antigen 3 (PCA3), TMPRSS2-ETS fusion gene, microRNA, and other regulatory non-coding RNAs. In addition, the prostate health index (PHI) has been approved by the U.S. Food and Drug Administration (FDA) for clinical use in the detection of PCa. The prostate-specific membrane antigen (PSMA) has been confirmed to be specifically expressed on the surface of PCa cells. In this review, we provide an updated summary of the value and features of these novel biomarkers in the diagnosis and treatment of PCa.
- 1 January 2019
- Published by Tech Science Press in BIOCELL
- Vol. 43 (3) , 207-213
SPAG9 promotes prostate cancer growth and metastasis
- 1 January 2019
- Published by Tech Science Press in BIOCELL
- Vol. 43 (3) , 207-213
SPAG9 promotes prostate cancer growth and metastasis
- Open Access
- 1 January 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 391-395
CART cell therapy for prostate cancer: status and promise
In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy.
- 1 January 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 391-395
Open AccessCART cell therapy for prostate cancer: status and promise
In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy.
- Open Access
- 17 June 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (57) , 97693-97700
Exosomes in diagnosis and therapy of prostate cancer
Oncotarget | https://doi.org/10.18632/oncotarget.18532 Jun Pan, Meng Ding, Kai Xu, Chunhua Yang, Li-Jun Mao Exosomes in diagnosis and therapy of prostate cancer
- 17 June 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (57) , 97693-97700
Open AccessExosomes in diagnosis and therapy of prostate cancer
Oncotarget | https://doi.org/10.18632/oncotarget.18532 Jun Pan, Meng Ding, Kai Xu, Chunhua Yang, Li-Jun Mao Exosomes in diagnosis and therapy of prostate cancer